{
    "clinical_study": {
        "@rank": "45436", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give efavirenz plus\n      stavudine plus lamivudine to patients who have never taken anti-HIV drugs."
        }, 
        "brief_title": "A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be given combination treatment with efavirenz, stavudine, and lamivudine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documented diagnosis of HIV infection with plasma HIV-RNA greater than or equal to\n             10,000 copies/ml.\n\n          -  Life expectancy of at least 12 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Current bilateral peripheral neuropathy greater than or equal to Grade 2.\n\n          -  Proven or suspected acute hepatitis due to any cause.\n\n          -  Recurrent episodes of moderate to severe diarrhea, or vomiting lasting for more than\n             4 days within 3 months prior to dosing.\n\n          -  Hypersensitivity to any component of the formulation of efavirenz, stavudine, or\n             lamivudine.\n\n          -  Any clinically significant laboratory findings obtained during the screening\n             evaluation (see laboratory values).\n\n          -  Any clinically significant disease (other than HIV infection) or clinically\n             significant findings found during the screening of medical history or physical\n             examination.\n\n          -  Any malignancy that requires systemic therapy.\n\n          -  Any active AIDS-defining opportunistic infection or disease.\n\n        Concurrent Medication:\n\n        Excluded:\n\n        Astemizole, cisapride, clarithromycin, ketoconazole, itraconazole, midazolam, rifabutin,\n        rifampin, terfenadine, thalidomide, triazolam, vincristine, zalcitabine or any medications\n        contraindicated for concomitant use with stavudine or lamivudine as described in the\n        current information package insert.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of acute or chronic pancreatitis.\n\n          -  A life expectancy of less than 12 months.\n\n          -  Difficulty swallowing capsules/tablets.\n\n          -  Inability to communicate effectively with study personnel.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any other experimental drug within 30 days of introducing study treatment.\n\n          -  Vaccination within 3 weeks of screening visit.\n\n          -  Any prior antiretroviral therapy.\n\n          -  Interferon started within 30 days of initiating study treatment.\n\n        Risk Behavior:\n\n        Excluded:\n\n        Current alcohol or illicit drug use which interferes with patient's ability to follow\n        study regimen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002227", 
            "org_study_id": "281C", 
            "secondary_id": "DMP 266-043"
        }, 
        "intervention": [
            {
                "intervention_name": "Efavirenz", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Stavudine", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Efavirenz", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Stavudine", 
            "Lamivudine", 
            "Reverse Transcriptase Inhibitors", 
            "efavirenz"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20009"
                    }, 
                    "name": "Richard Elion"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20009"
                    }, 
                    "name": "The Whitman Walker Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brookline", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02445"
                    }, 
                    "name": "Community Research Initiative of New England"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43215"
                    }, 
                    "name": "Remington Davis Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "170330850"
                    }, 
                    "name": "The Milton S Hersey Med Ctr / Div of Hematology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mount Pleasant", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29464"
                    }, 
                    "name": "Coastal Carolina Research Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77006"
                    }, 
                    "name": "Montrose Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hampton", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23666"
                    }, 
                    "name": "Hampton Roads Med Specialists"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Lamivudine in Antiretroviral Therapy-Naive HIV-Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002227"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dupont Merck", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "Coastal Carolina Research Ctr": "32.794 -79.863", 
        "Community Research Initiative of New England": "42.332 -71.121", 
        "Hampton Roads Med Specialists": "37.03 -76.345", 
        "Montrose Clinic": "29.76 -95.369", 
        "Remington Davis Inc": "39.961 -82.999", 
        "Richard Elion": "38.895 -77.036", 
        "The Milton S Hersey Med Ctr / Div of Hematology": "40.286 -76.65", 
        "The Whitman Walker Clinic": "38.895 -77.036"
    }
}